title: Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients.
abstract: BACKGROUND
  Small cell cervical carcinoma (SCCC) is a rare, aggressive tumor with a poor prognosis. However, information in relation to its treatment is scarce due to the limited numbers of patients. The aim of this study was to establish whether platinum-based combination chemotherapy may by beneficial in this patient population.
  
  
  METHODS
  We carried out a multicenter, retrospective study comprising of 72 Chinese patients with SCCC. The patients were treated between 1995 and 2010 at Sun Yat-sen Memorial Hospital or the Cancer Center of Sun Yat-Sen University, and at the First Affiliated Hospital of Shantou University Medical College, China.
  
  
  RESULTS
  Of the 72 patients, 46/72 (63.9%) had Federation of Gynecology and Obstetrics (FIGO) stage Ia-Ib2 and 26/72 (36.1%) had stage IIa-IV disease. Surgery was performed in 63/72 (87.5%) patients, 61/72 (84.7%) patients received chemoradiotherapy and 35/72 (48.6%) received radiotherapy. The 3-year overall survival (OS) and disease-free survival (DFS) rates were as follows: Ia (100%, 100%); Ib1 (62%, 57%); Ib2 (53%, 48%); IIa (36%, 23%); IIb (29%, 21%); IIIb (50%, 50%); and IV (0%, 0%), respectively. The estimated 3-year OS and DFS rates in patients who received platinum-based combination chemotherapy (etoposide + cisplatin [EP], or paclitaxel + cisplatin [TP]) as part of their adjuvant treatment were 64.8% and 63.0%, respectively, compared to 25.2% and 22.0% in those who did not (P = 0.0003; P = 0.0003). Univariate analysis showed that platinum-based combination chemotherapy was associated with improved survival compared to other chemotherapy techniques or no chemotherapy (OS: HR = 0.227; 95% CI, 0.099-0.524; P = 0.001; DFS: HR = 0.210; 95% CI, 0.087-0.506; P = 0.001). Multivariate analysis identified FIGO stage, lymphatic metastasis and platinum-based combination chemotherapy as independent prognostic factors for improved survival in patients with SCCC.
  
  
  CONCLUSIONS
  Platinum-based combination chemotherapy (with EP or TP) can improve the 3-year survival outcomes in patients with SCCC. Therefore, it should be considered an important component in a future standardized treatment strategy for SCCC.
authors.affiliation: Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi, China. huanglong914@gmail.com.
authors.forename: Long
authors.initials: L
authors.lastname: Huang
authors.forename: Ling-Min
authors.initials: LM
authors.lastname: Liao
authors.forename: An-Wen
authors.initials: AW
authors.lastname: Liu
authors.forename: Jian-Bing
authors.initials: JB
authors.lastname: Wu
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Cheng
authors.forename: Jia-Xin
authors.initials: JX
authors.lastname: Lin
authors.forename: Min
authors.initials: M
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D044466:Asian People / Q000208:ethnology; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000188:drug therapy* / Q000208:ethnology; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000208:ethnology; D055815:Young Adult
chemical_list: D043823:Taxoids; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin